Search Results - "BRUCE, Ian N"

Trial of Anifrolumab in Active Systemic Lupus Erythematosus by Morand, Eric F, Furie, Richard, Tanaka, Yoshiya, Bruce, Ian N, Askanase, Anca D, Richez, Christophe, Bae, Sang-Cheol, Brohawn, Philip Z, Pineda, Lilia, Berglind, Anna, Tummala, Raj

“…A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores…”
Get full text

The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults by Gordon, Caroline, Amissah-Arthur, Maame-Boatemaa, Gayed, Mary, Brown, Sue, Bruce, Ian N., D'Cruz, David, Empson, Benjamin, Griffiths, Bridget, Jayne, David, Khamashta, Munther, Lightstone, Liz, Norton, Peter, Norton, Yvonne, Schreiber, Karen, Isenberg, David

Get full text

The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary by Gordon, Caroline, Amissah-Arthur, Maame-Boatemaa, Gayed, Mary, Brown, Sue, Bruce, Ian N, D'Cruz, David, Empson, Benjamin, Griffiths, Bridget, Jayne, David, Khamashta, Munther, Lightstone, Liz, Norton, Peter, Norton, Yvonne, Schreiber, Karen, Isenberg, David

Get full text

The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review by Sutton, Emily J., PhD, Davidson, Julie E., MPH, Bruce, Ian N., FRCP

“…Abstract Objectives We performed a systematic literature review to determine factors that influence damage and damage progression in SLE patients and how…”
Get full text

Current challenges in the development of new treatments for lupus by Dall'Era, Maria, Bruce, Ian N, Gordon, Caroline, Manzi, Susan, McCaffrey, Janis, Lipsky, Peter E

“…Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a considerable impact on patients' quality of life. Despite the plethora of clinical…”
Get more information

Drug-Induced Interstitial Lung Disease: A Systematic Review by Skeoch, Sarah, Weatherley, Nicholas, Swift, Andrew J, Oldroyd, Alexander, Johns, Christopher, Hayton, Conal, Giollo, Alessandro, Wild, James M, Waterton, John C, Buch, Maya, Linton, Kim, Bruce, Ian N, Leonard, Colm, Bianchi, Stephen, Chaudhuri, Nazia

“…Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous agents, but the risk often only becomes apparent after the marketing…”
Get full text

Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations by Reynolds, John A, McCarthy, Eoghan M, Haque, Sahena, Ngamjanyaporn, Pintip, Sergeant, Jamie C, Lee, Elaine, Lee, Eileen, Kilfeather, Stephen A, Parker, Ben, Bruce, Ian N

“…Patients with SLE display marked clinical and immunlogical heterogeneity. The purpose of the study was to investigate patterns of serum cytokines in patients…”
Get full text

The challenges in data integration - heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus by Le Sueur, Helen, Bruce, Ian N, Geifman, Nophar

“…Individual clinical trials and cohort studies are a useful source of data, often under-utilised once a study has ended. Pooling data from multiple sources…”
Get full text

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol by Al-Laith, Mariam, Jasenecova, Marianna, Abraham, Sonya, Bosworth, Aisla, Bruce, Ian N, Buckley, Christopher D, Ciurtin, Coziana, D'Agostino, Maria-Antonietta, Emery, Paul, Gaston, Hill, Isaacs, John D, Filer, Andrew, Fisher, Benjamin A, Huizinga, Thomas W J, Ho, Pauline, Jacklin, Clare, Lempp, Heidi, McInnes, Iain B, Pratt, Arthur G, Östor, Andrew, Raza, Karim, Taylor, Peter C, van Schaardenburg, Dirkjan, Shivapatham, Dharshene, Wright, Alison J, Vasconcelos, Joana C, Kelly, Joanna, Murphy, Caroline, Prevost, A Toby, Cope, Andrew P

“…We present a study protocol for a multi-centre, randomised, double-blind, parallel-group, placebo-controlled trial that seeks to test the feasibility,…”
Get full text

Correction: Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil by Akthar, Mumina, Nair, Nisha, Carter, Lucy M, Vital, Edward M, Sutton, Emily, McHugh, Neil, Bruce, Ian N, Reynolds, John A

Get full text

Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models by Reynolds, John A, Prattley, Jennifer, Geifman, Nophar, Lunt, Mark, Gordon, Caroline, Bruce, Ian N

“…Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune condition for which there are limited licensed therapies. Clinical trial design is…”
Get full text

Rheumatoid arthritis reprograms circadian output pathways by Poolman, Toryn M, Gibbs, Julie, Walker, Amy L, Dickson, Suzanna, Farrell, Laura, Hensman, James, Kendall, Alexandra C, Maidstone, Robert, Warwood, Stacey, Loudon, Andrew, Rattray, Magnus, Bruce, Ian N, Nicolaou, Anna, Ray, David W

“…We applied systems biology approaches to investigate circadian rhythmicity in rheumatoid arthritis (RA). We recruited adults (age 16-80 years old) with a…”
Get full text

Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus by Reynolds, John A., Haque, Sahena, Williamson, Kate, Ray, David W., Alexander, M. Yvonne, Bruce, Ian N.

“…Patients with systemic lupus erythematosus (SLE) have accelerated cardiovascular disease and dysfunctional endothelial repair mechanisms. Myeloid angiogenic…”
Get full text

Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort by Costello, R E, Humphreys, J H, Sergeant, J C, Haris, M, Stirling, F, Raza, K, van Schaardenburg, D, Bruce, Ian N

“…First-degree relatives (FDRs) of people with rheumatoid arthritis (RA) have a fourfold increased risk of developing RA. The Symptoms in Persons At Risk of…”
Get full text

Correction to: Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the Preclinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort by Costello, R E, Humphreys, J H, Sergeant, J C, Haris, M, Stirling, F, Raza, K, van Schaardenburg, D, Bruce, Ian N

“…An amendment to this paper has been published and can be accessed via the original article…”
Get full text

Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil by Akhtar, Mumina, Nair, Nisha, Carter, Lucy M, Vital, Edward M, Sutton, Emily, McHugh, Neil, Bruce, Ian N, Reynolds, John A

“…Systemic lupus erythematosus (SLE) is a clinically and biologically heterogeneous autoimmune disease. We explored whether the deconvolution of whole blood…”
Get full text

Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles by Reynolds, John A, Briggs, Tracy A, Rice, Gillian I, Darmalinggam, Sathya, Bondet, Vincent, Bruce, Ellen, Khan, Mumtaz, Haque, Sahena, Chinoy, Hector, Herrick, Ariane L, McCarthy, Eoghan M, Zeef, Leo, Hayes, Andrew, Duffy, Darragh, Parker, Ben, Bruce, Ian N

“…To investigate the relationships between interferon alpha (IFNα) and the clinical and serological phenotype of patients with systemic autoimmune rheumatic…”
Get full text

Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD) by Ellis, Jessica, McHugh, Neil, Pauling, John D, Bruce, Ian N, Charlton, Rachel, McGrogan, Anita, Skeoch, Sarah

“…ObjectiveTo obtain updated estimates on the incidence and prevalence of systemic lupus erythematosus (SLE) in the UK, over the period 1990–2020, using the…”
Get full text

Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria by van Vollenhoven, Ronald, Askanase, Anca D, Bomback, Andrew S, Bruce, Ian N, Carroll, Angela, Dall'Era, Maria, Daniels, Mark, Levy, Roger A, Schwarting, Andreas, Quasny, Holly A, Urowitz, Murray B, Zhao, Ming-Hui, Furie, Richard

“…Disease modification has become a well-established concept in several therapeutic areas; however, no widely accepted definition of disease modification exists…”
Get full text

Atherosclerosis in rheumatoid arthritis: is it all about inflammation? by Skeoch, Sarah, Bruce, Ian N.

“…Key Points The prevalence and rate of progression of atherosclerosis is increased in rheumatoid arthritis (RA), and atherosclerotic plaques in patients with RA…”
Get full text